bioRxivImmunology
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model
T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W.-t. He, O. Limbo, C. Smith, G. Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L. Peng, J. Ricketts, M. K. Ricciardi, S. A. Rawlings, D. M. Smith, D. Nemazee, J. R. Teijaro, J. E. Voss, R. Andrabi, , D. Burton
Abstract
The development of countermeasures to prevent and treat COVID-19 is a global health priority. In under 7 weeks, we enrolled a cohort of SARS-CoV-2-recovered participants, developed neutralization assays to interrogate serum and monoclonal antibody responses, adapted our high throughput antibody isolation, production and characterization pipeline to rapidly screen over 1000 antigen-specific antibodies, and established an animal model to test protection. We report multiple highly potent neutralizing antibodies (nAbs) and show that passive transfer of a nAb provides protection against high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs define protective epitopes to guide vaccine design.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model
J. Kreye, S. M. Reincke, … N. Osterrieder·bioRxiv·Aug 15, 2020
- Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
M. Imbrechts, W. Maes, … N. Geukens·bioRxiv·Nov 25, 2021
- Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner
F. Amanat, S. Strohmeier, … F. Krammer·bioRxiv·Apr 5, 2021
- Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects
M. Jennewein, A. MacCamey, … L. Stamatatos·bioRxiv·Mar 23, 2021
- Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients
- LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
B. E. Jones, P. L. Brown-Augsburger, … M. de Vries·bioRxiv·Sep 30, 2020